This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our and .
Transport & Logistics
Interview with Michael Frost of COAG Reform Council
We have the opportunity to interview with Michael Frost, Executive Director of Capital Cities Strategic Planning Systems, COAG Reform Council. 1) Australian cities are facing major challenges in the near future. Population figures are projected to rise significantly within the next few decades. Urban congestion is inhibiting economic growth and is estimated to cost billions…
29 Apr 2011, by Informa InsightsHealthcare
Rising patient numbers and novel products are set to drive growth in the Chinese antidiabetics market
Melbourne, March 23, 2011 – Driven by the growing diabetic population and the improved healthcare insurance coverage implemented as part of the country's 2009 healthcare reform, the value of the overall diabetes drugs market in China will triple from $0.7bn in 2009 to $2.1bn in 2019, according to a new report from independent market analyst,…
25 Mar 2011, by Informa InsightsHealthcare
The Chinese hepatitis B market is set to triple by 2019
Melbourne, March15, 2011 – Fueled by the world’s largest hepatitis B patient pool, uptake of new therapies such as PEGylated interferons and Viread (tenofovir), and the government’s latest healthcare reforms, the Chinese hepatitis B market is set to continue its recent growth, and to triple in size by 2019, according to the latest analysis by…
15 Mar 2011, by Informa InsightsHealthcare
Battle against MRSA to net pharma industry US$2bn
Melbourne, 7th March 2011 - A number of new and expensive hospital brands targeting serious infections caused by multidrug-resistant bacteria, particularly MRSA*, will launch over the next decade. These will generate revenues totalling nearly US$2bn by 2019, according to independent market analyst Datamonitor.** However, the forecasted upside provided by these pipeline products will be insufficient…
7 Mar 2011, by Informa InsightsHealthcare
Will Australian Pharma ever be the same again?
Melbourne, 22nd February 2011 - The Australian pharmaceutical industry landscape is set to dramatically alter as a result of government changes to the Pharmaceutical Benefits Scheme (PBS), suggests independent market analyst, Datamonitor. Datamonitor’s outlook for the future includes withdrawn products, a struggling generics sector and wholesaler reorganization, as PBS reforms take effect. Erin Brady, Australian…
23 Feb 2011, by Informa InsightsHealthcare
Breast cancer cases on the rise in Japan
Melbourne, 18th February 2011. The number of women diagnosed with breast cancer per year in the seven major markets is forecast to increase by 13% over the next decade, finds independent healthcare analyst, Datamonitor.* However, in Japan, breast cancer incidence rates will rise by approximately 24% to 2019 to reach 56,400 cases, compared to 45,600…
18 Feb 2011, by Informa InsightsHealthcare
Diabetes pipeline cannot reverse cardiovascular and metabolic market decline
Melbourne, 10th February 2011 - Strong diabetes growth will not be enough to stop the cardiovascular and metabolic market from declining, finds independent market analyst Datamonitor.* Datamonitor forecasts that the cardiovascular and metabolic market across the seven major markets** will peak in 2011 and then begin to decline, with total sales falling from $105bn in…
10 Feb 2011, by Informa InsightsHealthcare
Can India become a biosimilar powerhouse?
Melbourne, 8th February 2011 - Indian manufacturers are ideally placed to capitalise on the growing biosimilars market, according to independent market analyst Datamonitor. Although the biosimilars market is in its infancy, Datamonitor research suggests that Indian manufacturers are well positioned to capitalise on the future growth of this market both domestically and internationally. Alistair Sinclair,…
8 Feb 2011, by Informa InsightsHealthcare
Rapidly deteriorating growth for Pharma
Melbourne, 21st January 2011. Growth will slow to just 1.3% to 2015 for the branded prescription pharmaceutical industry’s leading companies, according to latest research from independent market analyst, Datamonitor. Between 2003 and 2009, theses same companies enjoyed robust sales growth at a compound annual growth rate (CAGR) of 7.1%. Sharp declines in branded sales following…
21 Jan 2011, by Informa InsightsHealthcare
Stigma remains over Major Depressive Disorder
Melbourne, 12th January 2011 - Despite there being 39.1 million people suffering from major depressive disorder (MDD) across the seven major markets, only one third of patients will seek help from a physician, finds latest research from independent analyst Datamonitor*. Daniel Chancellor, healthcare analyst at Datamonitor, comments: “This is due to the stigma that is…
12 Jan 2011, by Informa InsightsHealthcare
Driven by strong market growth, Big Pharma’s interest in China is set to increase
Melbourne, 15th December 2010 – Rapid population growth as well as the increasing number of elderly people in China have created additional pressure on the government in terms of healthcare provision. In order to improve healthcare access, the Chinese government will spend $124.6 billion on healthcare reforms between 2009 and 2011 according to the latest…
15 Dec 2010, by Informa InsightsTransport & Logistics
Informa Interview – Captain Allan Gray on Master Mariners of Australia Congress
[youtube=http://www.youtube.com/watch?v=HA4RYdKBT00] We had the opportunity to interview Captain Allan Gray, Federal Master of the Company of Master Mariners of Australia who will be speaking at the inaugural Master Mariners of Australia Congress on the 7th and 8th April 2011 in Fremantle, WA, Australia. 1. The Company of Master Mariners is hosting its inaugural Master…
6 Dec 2010, by Informa Insights